NCT01128543 - Lapatinib in Combination With Vinorelbine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Cancer

Interventions

DRUG

lapatinib and Vinorelbine

Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.

Trial Locations (8)

GSK Investigational Site, Diyarbakır

GSK Investigational Site, Istanbul

GSK Investigational Site, Istanbul

GSK Investigational Site, Kayseri

GSK Investigational Site, Diskapi / Ankara

GSK Investigational Site, Ankara

GSK Investigational Site, Ankara

GSK Investigational Site, Ankara